- Home
- ACHR vs LEGN Comparison
ACHR vs LEGN Comparison
Compare ACHR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHR | LEGN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHR | LEGN |
|---|---|---|
| Price | $8.85 | $22.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $12.14 | ★ $69.33 |
| AVG Volume (30 Days) | ★ 39.1M | 2.1M |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $909,045,000.00 |
| Revenue This Year | N/A | $68.20 |
| Revenue Next Year | N/A | $47.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $5.48 | $20.21 |
| 52 Week High | $14.62 | $45.30 |
Technical Indicators
Market Signals| Indicator | ACHR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 42.47 |
| Support Level | $8.15 | $20.21 |
| Resistance Level | $9.29 | $24.12 |
| Average True Range (ATR) | 0.50 | 1.05 |
| MACD | 0.10 | 0.30 |
| Stochastic Oscillator | 76.48 | 47.57 |
Price Performance
Historical ComparisonAbout ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.